Zhejiang Tianyu Pharmaceutical (300702.SZ): CDE evaluation of the raw material drug p-toluene sulfonic acid atorvastatin.

Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Jingsheng Pharmaceutical Co., Ltd. (referred to as "Jingsheng Pharmaceutical") recently received approval from the China Drug Evaluation Center (CDE) of the National Medical Products Administration for the active pharmaceutical ingredient of edoxaban tosylate. The announcement stated that edoxaban tosylate is used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors such as congestive heart failure, hypertension, age 75 years, diabetes, history of prior stroke, or transient ischemic attack (TIA); it is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, as well as to prevent recurrence of DVT and PE in adults.